Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver
1989367 citationsPeter Ferenci, B Dragosics et al.Journal of Hepatologyprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of L Benda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L Benda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L Benda more than expected).
This network shows the impact of papers produced by L Benda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L Benda. The network helps show where L Benda may publish in the future.
Co-authorship network of co-authors of L Benda
This figure shows the co-authorship network connecting the top 25 collaborators of L Benda.
A scholar is included among the top collaborators of L Benda based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with L Benda. L Benda is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Ferenci, Peter, B Dragosics, H. Dittrich, et al.. (1989). Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. Journal of Hepatology. 9(1). 105–113.367 indexed citations breakdown →
2.
Benda, L, et al.. (1980). [The influence of therapy with silymarin on the survival rate of patients with liver cirrhosis (author's transl)].. PubMed. 92(19). 678–83.14 indexed citations
3.
Ambrosch, F, et al.. (1977). [Experimental investigations on the effect of various doses of streptokinase on blood viscosity (author's transl)].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 89(10). 350–3.1 indexed citations
4.
Benda, L, et al.. (1976). [Fibrinolysis and anticoagulants in severe angina pectoris].. PubMed. 126(1-3). 1–9.3 indexed citations
5.
Benda, L & Werner Zenz. (1973). [Silymarin in liver cirrhosis].. PubMed. 123(3). 512–6.5 indexed citations
6.
Benda, L. (1969). [Doxycycline in inflammatory diseases of the biliary tract].. PubMed. 119(33). 567–72.2 indexed citations
7.
Benda, L, et al.. (1966). [Clinical studies on the cardiotonic effects of proscillaridin A].. PubMed. 78(6). 106–9.1 indexed citations
8.
Benda, L, et al.. (1964). [THE EFFECT OF SEGONTIN PHENYLPROPYLDIPHENYLPROPYLAMINE) ON ENERGY-RICH PHOSPHATE COMPOUNDS IN THE HEART MUSCLE DURING OXYGEN DEFICIENCY].. PubMed. 45. 516–23.1 indexed citations
9.
Benda, L, et al.. (1960). [Clinical and experimental studies on the effect of cocarboxylase in heart diseases].. PubMed. 55. 775–8.1 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.